哮喘降级治疗的证据与实践重庆--培训课件.pptVIP

Response to mannitol and percentage sputum eosinophils were significantly greater before a failed ICS reduction than before the last successful ICS reduction, whereas there were no significant differences in symptoms, spirometry, or eNO * * * Figure 4 Change from baseline in morning peak expiratory flow for patients who received montelukast 10 mg once daily t budesonide 400 mg twice daily or budesonide 800 mg twice daily. (A) All patients, (B) patients with asthma and concomitant allergic rhinitis, (C) patients with concomitant rhinitis requiring regular treatment. From Price et al.53 Adapted